Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anticancer agent 105, a thienopyrimidine scaffold-based compound, exhibits selective toxicity towards melanoma and induces apoptosis. Additionally, it significantly inhibits metastatic nodules, including in a pulmonary metastatic melanoma mouse model [1], while demonstrating good safety and anticancer properties.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | Inquiry | 8-10 weeks | |
50 mg | Inquiry | 8-10 weeks |
Description | Anticancer agent 105, a thienopyrimidine scaffold-based compound, exhibits selective toxicity towards melanoma and induces apoptosis. Additionally, it significantly inhibits metastatic nodules, including in a pulmonary metastatic melanoma mouse model [1], while demonstrating good safety and anticancer properties. |
In vitro | Anticancer agent 105 (compound 9cb) shows selectivity against cancer cells with an IC50 of 2.41 μM for B16-F10 melanoma cells, while exceeding 100 μM for normal fibroblasts (MEF NF2) [1]. At 0.5-10 μM over 24 hours, it exhibits cytotoxic effects on cancer cells, and at 5-20 μM over 48 hours, it induces apoptosis and necrosis in B16-F10 cells [1]. |
In vivo | Anticancer agent 105 [compound 9cb] at a dosage of 9-9.5 mg/kg administered intraperitoneally every three days for a duration of 22 days, inhibited metastatic nodules in C57BL/6 mice bearing B16-F10 melanoma [1]. |
Molecular Weight | 533.64 |
Formula | C25H24KN3O6S |
Cas No. | 2450987-57-0 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.